<?xml version="1.0" encoding="UTF-8"?>
<p id="p0170">TV003/TV005 is a tetravalent live attenuated vaccine which includes three DENV serotypes (DENV-1, -3, âˆ’4) that have undergone attenuation through direct mutagenesis (a 30 base-pair deletion), while the DENV-2 candidate consists of a DENV-4-DENV-2 chimera. The Butantan Institute in Brazil, which is the sponsor of Butantan-DV (TV003), received regulatory approval in December 2015 to begin a Phase 3 trial in Brasil.</p>
